CY1124767T1 - Rna για τη θεραπεια αυτοανοσων ασθενειων - Google Patents
Rna για τη θεραπεια αυτοανοσων ασθενειωνInfo
- Publication number
- CY1124767T1 CY1124767T1 CY20211100867T CY211100867T CY1124767T1 CY 1124767 T1 CY1124767 T1 CY 1124767T1 CY 20211100867 T CY20211100867 T CY 20211100867T CY 211100867 T CY211100867 T CY 211100867T CY 1124767 T1 CY1124767 T1 CY 1124767T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rna
- autoimmune diseases
- treatment
- autoantigen
- development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μη ανοσογονικό RNA. Αυτό το RNA αποτελεί τη βάση για την ανάπτυξη θεραπευτικών παραγόντων για την επαγωγή ανοχής προς ένα αυτοαντιγόνο και επομένως, για τη θεραπεία αυτοάνοσων ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/058651 WO2018188730A1 (en) | 2017-04-11 | 2017-04-11 | Rna for treatment of autoimmune diseases |
PCT/EP2018/059188 WO2018189193A1 (en) | 2017-04-11 | 2018-04-10 | Rna for treatment of autoimmune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124767T1 true CY1124767T1 (el) | 2022-11-25 |
Family
ID=58632945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100867T CY1124767T1 (el) | 2017-04-11 | 2021-10-06 | Rna για τη θεραπεια αυτοανοσων ασθενειων |
Country Status (22)
Country | Link |
---|---|
US (2) | US11701413B2 (el) |
EP (2) | EP3981424A1 (el) |
JP (3) | JP7078641B2 (el) |
KR (2) | KR20190134765A (el) |
CN (1) | CN110719787B (el) |
AU (1) | AU2018253352A1 (el) |
BR (1) | BR112019020667A8 (el) |
CA (1) | CA3059505A1 (el) |
CY (1) | CY1124767T1 (el) |
DK (1) | DK3609529T3 (el) |
ES (1) | ES2893451T3 (el) |
HR (1) | HRP20211559T1 (el) |
HU (1) | HUE056871T2 (el) |
IL (2) | IL269793B (el) |
LT (1) | LT3609529T (el) |
MX (1) | MX2019012144A (el) |
PL (1) | PL3609529T3 (el) |
PT (1) | PT3609529T (el) |
RS (1) | RS62582B1 (el) |
SG (2) | SG11201909520VA (el) |
SI (1) | SI3609529T1 (el) |
WO (2) | WO2018188730A1 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020102172A2 (en) * | 2018-11-12 | 2020-05-22 | Translate Bio, Inc. | Methods for inducing immune tolerance |
US11161892B1 (en) | 2020-12-07 | 2021-11-02 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
CN115232825B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的新冠病毒疫苗 |
US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
JP2024520030A (ja) | 2021-05-26 | 2024-05-21 | アンシス・エスア | 自己免疫疾患を処置又は予防する方法 |
AR126654A1 (es) | 2021-06-29 | 2023-11-01 | Imcyse Sa | Péptidos y métodos para el tratamiento de neuromielitis óptica |
CN113336862B (zh) * | 2021-07-05 | 2022-03-01 | 广东省科学院动物研究所 | 一种抗多发性硬化的重组蛋白及其制备方法和用途 |
WO2023030635A1 (en) | 2021-09-02 | 2023-03-09 | BioNTech SE | Potency assay for therapeutic potential of coding nucleic acid |
WO2023131254A1 (zh) * | 2022-01-06 | 2023-07-13 | 上海吉量医药工程有限公司 | N1位修饰假尿嘧啶核苷及其在mRNA合成中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7030098B2 (en) * | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
AU2002952834A0 (en) | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
SI3611266T1 (sl) | 2005-08-23 | 2023-02-28 | The Trustees Of The University Of Pennsylvania | Modificirani nukleozidi, ki vsebujejo RNA, in postopki za njihovo uporabo |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
EP2050814A1 (en) | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
SI3112467T1 (en) | 2009-12-07 | 2018-06-29 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
US9778250B2 (en) * | 2011-05-10 | 2017-10-03 | The Brigham And Women's Hospital, Inc. | Detecting inclusion body myositis |
WO2013044419A1 (en) * | 2011-09-30 | 2013-04-04 | Beijing Advaccine Biotechnology Co., Ltd. | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases |
HUE047947T2 (hu) | 2011-12-30 | 2020-05-28 | Cellscript Llc | In vitro szintetizált ssRNS elõállítása és alkalmazása emlõssejtekbe történõ bevezetésre biológiai vagy biokémiai hatás indukálására |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
US20180303925A1 (en) * | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
CN106395552B (zh) | 2015-08-03 | 2020-03-17 | 奥的斯电梯公司 | 无绳电梯系统导轨组件 |
US10808242B2 (en) * | 2015-08-28 | 2020-10-20 | Biontech Rna Pharmaceuticals Gmbh | Method for reducing immunogenicity of RNA |
MX2018012880A (es) * | 2016-04-22 | 2019-03-28 | Biontech Rna Pharmaceuticals Gmbh | Metodos para proporcionar arn de hebra sencilla. |
-
2017
- 2017-04-11 WO PCT/EP2017/058651 patent/WO2018188730A1/en active Application Filing
-
2018
- 2018-04-10 SI SI201830424T patent/SI3609529T1/sl unknown
- 2018-04-10 BR BR112019020667A patent/BR112019020667A8/pt unknown
- 2018-04-10 KR KR1020197033154A patent/KR20190134765A/ko not_active Application Discontinuation
- 2018-04-10 LT LTEPPCT/EP2018/059188T patent/LT3609529T/lt unknown
- 2018-04-10 EP EP21191317.3A patent/EP3981424A1/en active Pending
- 2018-04-10 US US16/500,005 patent/US11701413B2/en active Active
- 2018-04-10 DK DK18717580.7T patent/DK3609529T3/da active
- 2018-04-10 KR KR1020247008874A patent/KR20240042138A/ko active Search and Examination
- 2018-04-10 MX MX2019012144A patent/MX2019012144A/es unknown
- 2018-04-10 SG SG11201909520V patent/SG11201909520VA/en unknown
- 2018-04-10 WO PCT/EP2018/059188 patent/WO2018189193A1/en unknown
- 2018-04-10 JP JP2019555957A patent/JP7078641B2/ja active Active
- 2018-04-10 CN CN201880024391.7A patent/CN110719787B/zh active Active
- 2018-04-10 HR HRP20211559TT patent/HRP20211559T1/hr unknown
- 2018-04-10 CA CA3059505A patent/CA3059505A1/en active Pending
- 2018-04-10 HU HUE18717580A patent/HUE056871T2/hu unknown
- 2018-04-10 RS RS20211224A patent/RS62582B1/sr unknown
- 2018-04-10 SG SG10202111163VA patent/SG10202111163VA/en unknown
- 2018-04-10 AU AU2018253352A patent/AU2018253352A1/en active Pending
- 2018-04-10 PT PT187175807T patent/PT3609529T/pt unknown
- 2018-04-10 ES ES18717580T patent/ES2893451T3/es active Active
- 2018-04-10 EP EP18717580.7A patent/EP3609529B1/en active Active
- 2018-04-10 PL PL18717580T patent/PL3609529T3/pl unknown
-
2019
- 2019-10-03 IL IL269793A patent/IL269793B/en unknown
-
2021
- 2021-10-06 CY CY20211100867T patent/CY1124767T1/el unknown
-
2022
- 2022-02-28 IL IL290980A patent/IL290980A/en unknown
- 2022-05-19 JP JP2022082384A patent/JP7444924B2/ja active Active
-
2023
- 2023-06-12 US US18/333,273 patent/US20230330198A1/en active Pending
-
2024
- 2024-02-22 JP JP2024025246A patent/JP2024059794A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124767T1 (el) | Rna για τη θεραπεια αυτοανοσων ασθενειων | |
CY1124845T1 (el) | Μεθοδοι παροχης μονοκλωνου rna | |
CY1123693T1 (el) | Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων | |
CY1122981T1 (el) | Συνθεσεις για διαμορφωση της εκφρασης του c9orf72 | |
CY1124487T1 (el) | Στοχευμενοι παραγοντες υψηλης-συγγενειας σε συγκεκριμενο αντιγονο μεμβρανης για προστατη για ενδοακτινοθεραπεια καρκινου του προστατη | |
CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
CY1122480T1 (el) | Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας | |
CY1121473T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
SV2017005380A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
CY1125938T1 (el) | Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου | |
CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
CY1124704T1 (el) | Παραγωγα sobetirome | |
EA201790192A1 (ru) | СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА | |
CY1117654T1 (el) | Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
EA201991997A1 (ru) | Комбинированная терапия | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
CY1124699T1 (el) | Ενωσεις | |
CY1124759T1 (el) | Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης | |
CY1121427T1 (el) | Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς | |
CY1123116T1 (el) | Θεραπευτικη αντιμετωπιση των αυτοανοσων διαταραχων με cd154 αντισωματα |